On October 22,
Yichang Renfu Pharmaceutical Co., Ltd.
(hereinafter referred to as "Yichang Renfu ")
held a national launch conference for domestic clobazhan
Yichang Renfu President Du Wentao introduced at the press conference that the specifications of this domestic clobazhan tablet are 10mg/piece, with 28 pieces per box, and a price of 84 yuan per box, "is the lowest price in the world."
"As a parent of a child with epilepsy, after the policy of importing clobazhan was implemented, I heard that domestic clobazhan tablets were also launched one after another. I was extremely excited. Our children's families can finally use clobazhan legally, and there is no need to worry about not being able to buy medicine."
Rare epilepsy disease group owner and patient Min Wen said that looking back at the entire process of clobazhan's listing, "a mixed feeling. Our problem was finally solved successfully, and it is inseparable from the country to the point of view." The unremitting efforts of the society. "
Lobazhan Tablets
belong to the second category of psychocontrol drug
has not been approved for sale in China for a long time
According to Red Star News , Lobazhan is a broad-spectrum anti-epileptic seizure drug for the treatment of rare epilepsy diseases and is used as an anti-epileptic drug in more than 100 countries.
However, Lobazhan belongs to the second category of psychocontrol drugs in my country.
has not been approved for sale in China for a long time.
The family members of children can only purchase the regular market from
Foreign agents.
Not long ago, Xiaofang reported that
1 Rare Disease The mother of the child
For the son of the child
, he purchased Lobazhan
for helping to receive and send drugs...
(click the picture below to review the details↓↓)
heartbreak! He bought life-saving medicine for his children and was actually considered drug trafficking! The procuratorate made a decision... After the publication of the report,
In December 2021, National Health Commission publicly responded that: It is organizing a survey of the diseased groups to understand the drug dosage needs, and coordinate relevant institutions and departments to organize centralized applications and imports in accordance with the relevant provisions of the Drug Administration Law to meet patients' medication needs.
March 29, 2022: National Health Commission issued an announcement to solicit opinions on the "Temporary Import Work Plan for Lobazhan" "In order to meet the urgent need for clinical drug use, the temporary import work plan for Lobazhan is formulated according to the relevant provisions of the "Temporary Import Work Plan for Clinical Urgent Drugs".
June 29, 2022: National Drug Administration issued " Notice on issuing the Work Plan for Temporary Import of Clinical Urgent Drugs and the Work Plan for Temporary Import of Clinical Urgents" stated that in order to further improve the policy of guaranteeing drugs for drug supply and meet the people's demand for small amounts of specific clinical urgently needed drugs that have been marketed abroad and have no supply in China, and take this opportunity to form a relatively complete temporary import plan for urgently needed drugs in clinically needed drugs, the National Health Commission and the State Drug Administration recently issued the "Work Plan for Temporary Import of Clinical Urgents" and the "Work Plan for Temporary Import of Clinical Urgents".
September 22 this year
Good news finally came
Lobazhan can finally buy
Temporary import Lobazhan first prescribed
in the country on Peking Union Medical College Hospital
Ms. Li can rest assured
(click the picture and text below to view details ↓↓)
This life-saving drug has finally been implemented! Some people have been accused of "drug trafficking" because of it...
Domestic cloba accounts for the important milestone in the development of the anti-epileptic cause
"The Global Epilepsy Report" released in 2019 shows that the risk of abnormal death or premature death in epilepsy patients is three times that of normal people, and epilepsy accounts for the fifth place in the global burden of disease, and is a very worthy of attention for social public health issues. There are 9 million epilepsy patients in my country, of which about 6 million are active epilepsy patients. The proportion of patients who fail to receive regular treatment due to various reasons is very high. The treatment gap for active epilepsy in my country is 63%, so the anti-epileptic cause has a long way to go.”
On October 22, Hong Zhen, president of China Anti-epileptic Association, said at the national market launch conference for domestic clobazhan that many relevant parties cooperated to respond quickly to and quickly launched the market with the rapid development of domestic clobazhan. completely solved the crisis of drug outage. is an important milestone event for the development of my country's anti-epileptics industry and .
Domestic clobazhan is officially launched. According to Oriental ICh
Du Wentao, in 2017, Yichang Renfu noticed the second batch of recommendations for children's drugs to be encouraged to apply for the project of clobazhan in the "Second Batch List of Recommendations for Drugs for R&D" released by the former National Health and Family Planning Commission and other institutions, and decided to apply for the project of clobazhan; last year, after the shortage of clobazhan drugs appeared, in order to solve the urgent drug demand for rare disease groups as soon as possible, the company increased its personnel and resources investment. Finally, in September this year, the clobazhan tablets produced by the company were approved for market launch.
"
" In order to better serve the clinical service and ensure the accessibility of drugs, the domestic clobazhan tablets produced by Yichang Renfu are priced at 84 yuan per box. I hope everyone sees our sincerity and hopes that this price meets everyone's expectations." Du Wentao said.
”
Du Wentao also said that after the drug is launched, the company will continue to carry out drug-related clinical research; at the same time, by participating in and organizing relevant academic conferences in the field of epilepsy, accurately conveying drug-related information and treatment knowledge to ensure patients' reasonable and safe use of clobazan.
In addition, in response to the demands of parents of children,
The company is preparing to launch in 2023 l1 Lobazhan tablets enter National Medical Insurance Directory Application Work
In the later stage, cooperation with third-party public welfare funds will also be prepared to provide medical assistance to patients in families with financial difficulties.
Source: Red Star News (Reporter: Wang Jianqiang), The Paper
Editor: Li Shijing
Click to share
